Clinical Trials Logo
  1. Home
  2. ARDS
  3. NCT05098106
  4. Details
NCT05098106 Clinical Trial

PLAIAR-Trial: Platelets in Inflammation and Resolution

ARDS Clinical Trial

— PLAIAR  

Official title:
PlaIaR-Trial: Platelets in Inflammation and Resolution.

Clinical Trial Details — Status: Recruiting

Administrative data
NCT number NCT05098106
Other study ID # 12-Anit-20
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2021
Est. completion date March 2023

Study information
Verified date October 2021
Source University Hospital Muenster
Contact Carola Wempe, Dr
Phone +4925147255
Email wempe-c@anit.uni-muenster.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Detection and determination of platelets in bronchoalveolar lavage fluid and blood in ARDS and non-ARDS-patients. Correlation with phenotype and inflammation parameters in blood and outcome parameters.

Recruitment information / eligibility
Status Recruiting
Enrollment 72
Est. completion date March 2023
Est. primary completion date March 2023
Accepts healthy volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Routine bronchoscopy - Patient in perioperative setting - Age >=18 years - Consent Exclusion Criteria: - Active or recent (in past 7 days) bleeding in upper airways - Recent traumatic injury of the lung associated with (micro-)hemorrhage - Blood aspiration - Pregnancy - Age<18 years - Acute kidney injury / Chronic kidney failure / Dialysis - Transplantation - HIV - Hematologic diseases - Immunosuppression - Anti-Platelet-Therapy

Study Design

Related Conditions & MeSH terms

Intervention

Diagnostic Test:
• Bronchoscopy, blood sampling; testing.
BAL and blood samples are measured by hematology analyzer, flow cytometry, western blot, RNAseq analysis and multiplex.

Locations
Country Name City State
Germany University Hospital Muenster Muenster

Sponsors (3)
Lead Sponsor Collaborator
University Hospital Muenster Principal Investigator: Dr. Andreas Margraf, Study Chair and Principal Investigator: Univ.-Prof. Dr. Alexander Zarbock

Country where clinical trial is conducted

Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Detectability and changes in platelets in BAL and blood 5-7 days
Primary Organ failure, survival. 1 Year
Primary Systemic platelet and leukocyte numbers 5-7 days
Primary Systemic platelet and leukocyte phenotypes. 5-7 days
Primary Systemic cytokine profiles. 5-7 days
See also
  Status Clinical Trial Phase
Completed NCT04435613 - Clinical and Physiological Assessment of a Nearly Ultra-protective Lung Ventilation Strategy: A Quasi-experimental Preliminary Study in ARDS Patients N/A
Enrolling by invitation NCT05020210 - Effect of Early Treatment With Sivelestat Sodium in ARDS Patients
Completed NCT04468971 - REgulatory T Cell infuSion fOr Lung Injury Due to COVID-19 PnEumonia Phase 1
Completed NCT04505592 - Tenecteplase in Patients With COVID-19 Phase 2
Completed NCT04493242 - Extracellular Vesicle Infusion Treatment for COVID-19 Associated ARDS Phase 2
Withdrawn NCT04909879 - Study of Allogeneic Adipose-Derived Mesenchymal Stem Cells for Non-COVID-19 Acute Respiratory Distress Syndrome Phase 2
Completed NCT02265198 - Relationship of Pulmonary Contusion to Pulmonary Inflammation and Incidence of Acute Respiratory Distress Syndrome N/A
Completed NCT01949272 - Optimization of PEEP for Alveolar Recruitment in ARDS N/A
Not yet recruiting NCT01668368 - Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance N/A
Completed NCT01881061 - Lung Sonography in Patients With Acute Respiratory Distress Syndrome in Intensive Care Unit N/A
Completed NCT00808691 - Microcirculation and Oxidative Stress in Critical Ill Patients in Surgical Intensive Care Unit N/A
Completed NCT05035589 - The Effect of Tocilizumab on Procalcitonin and Other Biochemical and Clinical Markers in the Setting of COVID-19 Pneumonia
Recruiting NCT04764032 - Right Ventricular Dysfunction in Ventilated Patients With COVID-19
Completed NCT04556513 - Functional Recovery From Acute Respiratory Distress Syndrome (ARDS) Due to COVID-19: Influence of Socio-Economic Status
Recruiting NCT06036056 - NMR Based Metabolomics Kinetics in ARDS Patients
Recruiting NCT04503876 - Effects of End-expiratory Positive Pressure Optimization in Intubated Patients With Healthy Lung or Acute Respiratory Distress Syndrome N/A
Recruiting NCT04643691 - Losartan and Spironolactone Treatment for ICU Patients With COVID-19 Suffering From ARDS Phase 2
Completed NCT04395911 - Safety and Efficacy of SCD in AKI or ARDS Patients Associated With COVID-19 Infections N/A
Not yet recruiting NCT05341687 - Prognostic Value of Respiratory System Compliance Under VV-ECMO on 180-day Mortality in COVID-19 ARDS.
Recruiting NCT05056090 - Effect of Prone Positioning on Mortality in Patients With Mild to Moderate Acute Respiratory Distress Syndrome. N/A